Eli Lilly and Company (NYSE:LLY) Shares Down 1.1% – Here’s Why

Eli Lilly and Company (NYSE:LLY)’s stock price dropped 1.1% during trading on Wednesday . The stock traded as low as $1,027.00 and last traded at $1,030.3040. Approximately 2,450,740 shares changed hands during trading, a decline of 27% from the average daily volume of 3,366,475 shares. The stock had previously closed at $1,042.15.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s clinical and competitive positioning strengthened after Novo Nordisk’s late‑stage CagriSema came up short versus Lilly’s tirzepatide, reinforcing Lilly’s leadership in obesity GLP‑1 therapies. Novo’s stumbles burnish Lilly’s lead (Reuters)
• Positive Sentiment: Lilly launched a multi‑dose Zepbound pen (month‑sized dosing), a commercial convenience that can support prescriptions and patient retention. This is a near‑term revenue catalyst and a defensive product advantage. Eli Lilly launches new weight-loss Zepbound KwikPen (Yahoo)
• Positive Sentiment: Positive Phase 3 VIVID‑2 open‑label extension results (mirikizumab) and completion of an early oral obesity trial are incremental clinical wins that diversify Lilly’s pipeline beyond injectable GLP‑1s. These reduce single‑product risk and support longer‑term growth expectations. VIVID-2 positive results (Yahoo) Oral obesity drug trial reaches completion (TipRanks)
• Neutral Sentiment: Bank research largely remains constructive — Goldman/other analysts keep buy ratings and conservative 2026 guidance is cited as evidence of capital flexibility; that underpins longer‑term analyst support even amid short‑term noise. Analyst views and buy ratings (TipRanks)
• Neutral Sentiment: BofA and other firms argue Novo’s announced list‑price cuts may primarily be a competitive/PR move and likely won’t meaningfully alter U.S. GLP‑1 market dynamics for incumbents like Lilly. That view tempers fears about durable revenue downside. BofA sees limited impact from Novo price update (Yahoo)
• Negative Sentiment: Novo Nordisk announced plans to cut U.S. list prices for Wegovy/Ozempic by up to ~50% starting in 2027, raising concerns about potential price pressure and margin impact across the GLP‑1 category. Markets reacted, adding near‑term downside risk for peers. Novo Nordisk unveils up to 50% US price cuts (Yahoo)
• Negative Sentiment: News of the planned price cuts and related headlines prompted selling pressure in Lilly shares (investors worried about category pricing dynamics), which is why LLY is retreating despite the company’s strong fundamentals. Eli Lilly slips as Novo to cut GLP-1 prices (Seeking Alpha)

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on LLY shares. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Eli Lilly and Company in a research note on Monday, December 22nd. Wolfe Research increased their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research note on Monday. Leerink Partners upped their price objective on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a report on Thursday, February 5th. Finally, Cantor Fitzgerald raised their target price on Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,229.33.

Eli Lilly and Company Trading Down 1.1%

The business has a 50 day moving average of $1,054.49 and a 200-day moving average of $923.72. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The firm has a market capitalization of $971.95 billion, a P/E ratio of 44.89, a PEG ratio of 1.23 and a beta of 0.39.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the previous year, the firm posted $5.32 earnings per share. The business’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 30.15%.

Institutional Trading of Eli Lilly and Company

Institutional investors have recently modified their holdings of the company. 10Elms LLP grew its stake in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 10 shares in the last quarter. M.E. Allison & CO. Inc. boosted its holdings in Eli Lilly and Company by 0.7% during the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock worth $1,587,000 after purchasing an additional 10 shares during the last quarter. Tanager Wealth Management LLP boosted its holdings in Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock worth $424,000 after purchasing an additional 10 shares during the last quarter. Morey & Quinn Wealth Partners LLC grew its position in Eli Lilly and Company by 1.5% in the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock valued at $710,000 after purchasing an additional 10 shares in the last quarter. Finally, Wealthspan Partners LLC increased its stake in Eli Lilly and Company by 0.5% in the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock valued at $2,268,000 after buying an additional 10 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.